Zenas BioPharma (ZBIO) Common Equity (2023 - 2026)

Zenas BioPharma's Common Equity history runs 4 years deep, the most recent figure standing at $335.8 million for Q1 2026.

• On a quarterly basis, Common Equity rose 18.12% year-over-year to $335.8 million in Q1 2026; TTM through Mar 2026 was $335.8 million, a 18.12% increase from a year earlier, with the FY2025 full-year figure at $242.1 million, down 22.5% from the prior year.
• Common Equity rose to $335.8 million in Q1 2026 per ZBIO's latest filing, from $242.1 million in the prior quarter.
• Across five years, Common Equity topped out at $359.4 million in Q3 2024 and bottomed at -$288.8 million in Q2 2024.
• The 4-year median for Common Equity is $239.6 million (2025), against an average of $91.0 million.
• Across the five-year window, Common Equity soared 277.73% in 2024 and plunged 45.35% in 2025, its largest moves.
• Year by year, Common Equity stood at -$225.7 million in 2023, then surged by 238.43% to $312.5 million in 2024, then fell by 22.5% to $242.1 million in 2025, then jumped by 38.69% to $335.8 million in 2026.
• Per Business Quant, the three latest ZBIO Common Equity figures stand at $335.8 million (Q1 2026), $242.1 million (Q4 2025), and $196.4 million (Q3 2025).